ANI Pharmaceuticals (Nasdaq:ANIP) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ANIP 주식 개요

는 미국과 캐나다에서 브랜드 및 일반 처방 의약품을 개발, 제조 및 판매하는 바이오 제약 회사입니다.

ANIP 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	3/6
과거 실적	2/6
재무 상태	5/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 66.8% 에서 거래

수익은 매년 31.18% 증가할 것으로 예상됩니다.

올해부터 흑자전환

분석가들은 주가가 34.3% 상승할 것이라는 데 동의합니다.

위험 분석

재무 결과에 영향을 미치는 대규모 일회성 항목

지난 1년 동안 주주가 희석되었습니다.

지난 3개월간 상당한 내부자 매도

ANI Pharmaceuticals, Inc. 경쟁사

Harmony Biosciences Holdings

NasdaqGM:HRMY

US$1.6b

Collegium Pharmaceutical

NasdaqGS:COLL

US$1.1b

Pacira BioSciences

NasdaqGS:PCRX

US$1.3b

Amphastar Pharmaceuticals

NasdaqGS:AMPH

US$2.0b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 ANI Pharmaceuticals
과거 주가
현재 주가	US$60.74
52주 최고치	US$70.81
52주 최저치	US$48.20
베타	0.81
11개월 변경	-1.57%
3개월 변경 사항	-12.70%
1년 변경 사항	17.85%
33년 변화	80.67%
5년 변화	-23.57%
IPO 이후 변화	864.13%

최근 뉴스 및 업데이트

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

Jun 10

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Jun 10

Recent updates

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

Jun 10

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Jun 10

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Feb 17

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Nov 15

주주 수익률

	ANIP	US Pharmaceuticals	US 마켓
7D	-4.0%	0.3%	0.7%
1Y	17.9%	17.4%	23.3%

수익률 대 산업: ANIP 지난 1년 동안 17.4 %를 반환한 US Pharmaceuticals 산업과 일치했습니다.

수익률 대 시장: ANIP 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is ANIP's price volatile compared to industry and market?
ANIP volatility
ANIP Average Weekly Movement	3.4%
Pharmaceuticals Industry Average Movement	9.7%
Market Average Movement	5.8%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.8%

안정적인 주가: ANIP 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: ANIP 의 주간 변동성( 3% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2001	642	Nikhil Lalwani	www.anipharmaceuticals.com

바이오 제약 회사인 ANI Pharmaceuticals는 미국과 캐나다에서 브랜드 및 일반 처방 의약품을 개발, 제조, 판매하는 회사입니다. 이 회사는 경구용 고형제, 반고형제, 액상제, 국소제, 규제 약물, 강력한 제품을 제조할 뿐만 아니라 의약품 위탁 개발 및 제조를 수행합니다. 이 회사는 소매 약국 체인, 도매업체, 유통업체 및 우편 주문 약국, 단체 구매 조직, 전문 약국 및 병원을 통해 제품을 판매합니다.

ANI Pharmaceuticals, Inc. 기본 사항 요약

ANI Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ANIP 기본 통계
시가총액	US$1.18b
수익(TTM)	US$30.55m
수익(TTM)	US$517.46m

38.6x

P/E 비율

2.3x

P/S 비율

ANIP 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ANIP 손익 계산서(TTM)
수익	US$517.46m
수익 비용	US$192.96m
총 이익	US$324.50m
기타 비용	US$293.95m
수익	US$30.55m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	1.57
총 마진	62.71%
순이익 마진	5.90%
부채/자본 비율	59.9%

ANIP 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ANIP 주식 개요

보상

위험 분석

ANI Pharmaceuticals, Inc. 경쟁사

NasdaqGM:HRMY

US$1.6b

NasdaqGS:COLL

US$1.1b

NasdaqGS:PCRX

US$1.3b

NasdaqGS:AMPH

US$2.0b

가격 내역 및 성능

최근 뉴스 및 업데이트

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Head of R&D notifies of intention to sell stock

President recently sold US$1.1m worth of stock

President notifies of intention to sell stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Head of R&D notifies of intention to sell stock

President recently sold US$1.1m worth of stock

President notifies of intention to sell stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024

ANI Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 10, 2024

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the Launch of Baclofen Oral Suspension

ANI Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

ANI Pharmaceuticals, Inc. Announces the Launch of Levofloxacin Oral Solution, USP

Consensus EPS estimates increase by 27%

Independent Director notifies of intention to sell stock

Price target increased by 7.5% to US$75.50

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ANI Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

ANI Pharmaceuticals, Inc. to Report Second Half, 2023 Results on Feb 29, 2024

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Indomethacin Oral Suspension, USP

Head of R&D notifies of intention to sell stock

Head of R&D notifies of intention to sell stock

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Head of Rare Disease recently sold US$157k worth of stock

New minor risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

New major risk - Revenue and earnings growth

ANI Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces Fda Approval and Commercial Availability of New 1-Ml Vial Size of Purified Cortrophin®? Gel, Appropriate for Adjunctive Treatment of Certain Patients with Acute Gouty Arthritis Flares

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Head of R&D notifies of intention to sell stock

Ani Pharmaceuticals Announces the Fda Approval and Launch of Estradiol Gel, 0.1%

ANI Pharmaceuticals, Inc. Announces Board Changes

Head of R&D notifies of intention to sell stock

President recently sold US$3.3m worth of stock

President notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023

ANI Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Profitability

Head of R&D notifies of intention to sell stock

Price target increased by 12% to US$55.00

Head of R&D notifies of intention to sell stock

ANI Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $75.000033 million.

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ANI Pharmaceuticals, Inc. Raises Revenue Guidance for Full Year 2023

Consensus EPS estimates fall by 42%, revenue upgraded

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 7.7% to US$46.60

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Levocarnitine Tablets USP

ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP

ANI Pharmaceuticals, Inc. Announces the FDA Approval and Launch of Trimethoprim Tablets USP

Consensus forecasts updated

High number of new directors